CHMP4B

Across TCGA pan-cancer cohorts, CHMP4B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CHMP4B data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CHMP4B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHMP4B expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

CCRCC, LSCC, and HNSC are the cancer types where CHMP4B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.302	0.787	.001	19	view →
LSCC	DFS	Tertile	All	0.999	0.900	.016	10	view →
HNSC	DFS	Median	II,III,IV	0.968	0.903	.035	5	view →
OV	DFS	Median	All	0.677	1.000	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CHMP4B–CCRCC (DFS)

Open the CCRCC breakdown →